Items | Enrollment (pre-operative) | Allocation (baseline) | Treatment (post-operative) | Follow-up | |||||
---|---|---|---|---|---|---|---|---|---|
Time point (hour/day) | -1 | -1 | 6 h | 1d | 2d | 3d | 5d | 7d | 10d |
Treatment sessions (n) | – | – |  | 1 | 2 | 3 |  |  |  |
Informed consent | √ |  |  |  |  |  |  |  |  |
Assessment of eligibility | √ |  |  |  |  |  |  |  |  |
VAS (resting) |  | √ | √ | √ | √ | √ | √ | √ | √ |
VAS (active) |  | √ |  | √ | √ | √ | √ | √ | √ |
Additional dose released by PCA pump |  |  |  |  | √ |  |  |  |  |
HSS score |  | √ |  |  |  | √ |  |  | √ |
HAMA score |  | √ |  |  |  | √ |  |  | √ |
AROM |  | √ |  |  |  | √ | √ | √ | √ |
PROM |  | √ |  |  |  | √ | √ | √ | √ |
COK |  |  |  | √ |  | √ | √ | √ | √ |
Discomfort and acceptance of EA |  |  |  | √ | √ | √ |  |  |  |
Assessment of blinding method |  |  |  |  |  | √ |  |  |  |
Postoperative complications and adverse events |  |  |  | √ | √ | √ |  |  |  |